Curr Opin Nephrol Hypertens 2021 May 10. Epub 2021 May 10.
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Division of Nephrology, University of Utah Health, Salt Lake City, Utah, USA University of Edinburgh/British Heart Foundation Centre of Research Excellence, Centre for Cardiovascular Science, Queen's Medical Research Institute Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
Purpose Of Review: To summarize new clinical findings of endothelin receptor antagonists (ERA) in various etiologies of kidney disease targeted in clinical trials.
Recent Findings: Endothelin-1 is a multifunctional peptide with potential relevance to glomerular and tubulointerstitial kidney diseases. The phase 3 SONAR trial demonstrated a significant reduction in clinically relevant kidney outcomes for patients with diabetic kidney disease (DKD) after long-term treatment with the ERA, atrasentan, in addition to blockade of the renin-angiotensin-aldosterone system. Read More